Suppr超能文献

男性复发性尿道狭窄的尿道切开术与开放尿道成形术的比较:OPEN RCT。

Open urethroplasty versus endoscopic urethrotomy for recurrent urethral stricture in men: the OPEN RCT.

机构信息

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Health Services Research Unit, University of Aberdeen, Aberdeen, UK.

出版信息

Health Technol Assess. 2020 Nov;24(61):1-110. doi: 10.3310/hta24610.

Abstract

BACKGROUND

Men who suffer recurrence of bulbar urethral stricture have to decide between endoscopic urethrotomy and open urethroplasty to manage their urinary symptoms. Evidence of relative clinical effectiveness and cost-effectiveness is lacking.

OBJECTIVES

To assess benefit, harms and cost-effectiveness of open urethroplasty compared with endoscopic urethrotomy as treatment for recurrent urethral stricture in men.

DESIGN

Parallel-group, open-label, patient-randomised trial of allocated intervention with 6-monthly follow-ups over 24 months. Target sample size was 210 participants providing outcome data. Participants, clinicians and local research staff could not be blinded to allocation. Central trial staff were blinded when needed.

SETTING

UK NHS with recruitment from 38 hospital sites.

PARTICIPANTS

A total of 222 men requiring operative treatment for recurrence of bulbar urethral stricture who had received at least one previous intervention for stricture.

INTERVENTIONS

A centralised randomisation system using random blocks allocated participants 1 : 1 to open urethroplasty (experimental group) or endoscopic urethrotomy (control group).

MAIN OUTCOME MEASURES

The primary clinical outcome was control of urinary symptoms. Cost-effectiveness was assessed by cost per quality-adjusted life-year (QALY) gained over 24 months. The main secondary outcome was the need for reintervention for stricture recurrence.

RESULTS

The mean difference in the area under the curve of repeated measurement of voiding symptoms scored from 0 (no symptoms) to 24 (severe symptoms) between the two groups was -0.36 [95% confidence interval (CI) -1.78 to 1.02;  = 0.6]. Mean voiding symptom scores improved between baseline and 24 months after randomisation from 13.4 [standard deviation (SD) 4.5] to 6 (SD 5.5) for urethroplasty group and from 13.2 (SD 4.7) to 6.4 (SD 5.3) for urethrotomy. Reintervention was less frequent and occurred earlier in the urethroplasty group (hazard ratio 0.52, 95% CI 0.31 to 0.89;  = 0.02). There were two postoperative complications requiring reinterventions in the group that received urethroplasty and five, including one death from pulmonary embolism, in the group that received urethrotomy. Over 24 months, urethroplasty cost on average more than urethrotomy (cost difference £2148, 95% CI £689 to £3606) and resulted in a similar number of QALYs (QALY difference -0.01, 95% CI -0.17 to 0.14). Therefore, based on current evidence, urethrotomy is considered to be cost-effective.

LIMITATIONS

We were able to include only 69 (63%) of the 109 men allocated to urethroplasty and 90 (80%) of the 113 men allocated to urethrotomy in the primary complete-case intention-to-treat analysis.

CONCLUSIONS

The similar magnitude of symptom improvement seen for the two procedures over 24 months of follow-up shows that both provide effective symptom control. The lower likelihood of further intervention favours urethroplasty, but this had a higher cost over the 24 months of follow-up and was unlikely to be considered cost-effective.

FUTURE WORK

Formulate methods to incorporate short-term disutility data into cost-effectiveness analysis. Survey pathways of care for men with urethral stricture, including the use of enhanced recovery after urethroplasty. Establish a pragmatic follow-up schedule to allow national audit of outcomes following urethral surgery with linkage to NHS Hospital Episode Statistics.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN98009168.

FUNDING

This project was funded by the NIHR Health Technology Assessment programme and will be published in full in ; Vol. 24, No. 61. See the NIHR Journals Library website for further project information.

摘要

背景

患有球部尿道狭窄复发的男性必须在腔内尿道切开术和开放性尿道成形术之间做出选择,以治疗其尿路症状。缺乏相对临床效果和成本效益的证据。

目的

评估开放性尿道成形术与腔内尿道切开术治疗男性复发性尿道狭窄的疗效、危害和成本效益。

设计

平行组、开放标签、患者随机试验,分配干预措施,随访 6 个月,共 24 个月。目标样本量为 210 名提供结局数据的参与者。参与者、临床医生和当地研究人员无法对分配情况进行盲法。当需要时,中央试验工作人员会进行盲法。

地点

英国 NHS,在 38 家医院进行招募。

参与者

总共 222 名需要手术治疗球部尿道狭窄复发的男性,他们之前至少接受过一次狭窄治疗。

干预措施

使用随机块的中央随机化系统,将参与者以 1:1 的比例随机分配到开放性尿道成形术(实验组)或腔内尿道切开术(对照组)。

主要结局测量

主要临床结局是控制尿路症状。通过在 24 个月内获得的质量调整生命年(QALY)的成本进行成本效益评估。主要次要结局是复发性狭窄需要再次干预的情况。

结果

两组间重复测量排尿症状的曲线下面积的平均差异为-0.36 [95%置信区间(CI)-1.78 至 1.02; = 0.6]。随机分组后 24 个月,两组的平均排尿症状评分从基线时的 13.4 [标准差(SD)4.5]改善至 6(SD 5.5),分别为尿道成形术组和从 13.2(SD 4.7)到 6.4(SD 5.3),尿道切开术组。尿道成形术组的再干预频率较低,且发生较早(风险比 0.52,95%CI 0.31 至 0.89; = 0.02)。接受尿道成形术的组中有两例术后并发症需要再次干预,接受尿道切开术的组中有五例,包括一例因肺栓塞死亡。在 24 个月内,尿道成形术的平均成本高于尿道切开术(成本差异为 2148 英镑,95%CI 689 至 3606 英镑),并且产生了相似数量的 QALY(QALY 差异为-0.01,95%CI -0.17 至 0.14)。因此,根据现有证据,尿道切开术被认为具有成本效益。

局限性

我们仅能够纳入分配到尿道成形术的 109 名男性中的 69 名(63%)和分配到尿道切开术的 113 名男性中的 90 名(80%)进行主要完全病例意向治疗分析。

结论

两种手术在 24 个月的随访中观察到相似程度的症状改善,表明两者均能有效控制症状。进一步干预的可能性较低有利于尿道成形术,但在 24 个月的随访中成本较高,不太可能被认为具有成本效益。

未来工作

制定方法将短期不适数据纳入成本效益分析。调查男性尿道狭窄的治疗途径,包括使用尿道成形术后的快速康复。制定一个实用的随访计划,允许对尿道手术后的结果进行全国性审计,并与 NHS 医院入院统计数据进行链接。

试验注册

当前对照试验 ISRCTN98009168。

资金

本项目由英国国家卫生与保健优化研究所卫生技术评估计划资助,将在 ;第 24 卷,第 61 期。有关该项目的更多信息,请访问 NIHR 期刊库网站。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验